Aclarion, Inc. (NASDAQ: ACON) shares surged 50% on Thursday with another update on their Nociscan technology. The company presented a cost-effectiveness abstract on Nociscan cost at the International Society for the Advancement of Spine Surgery on Saturday, June 3, 2023. The cost-effectiveness study comparing Nociscan to Provocative Discography (PD) was performed at the Center for Disruptive Musculoskeletal Innovations (CDMI) through a National Science Foundation (NSF) grant sponsored by Aclarion. The abstract highlights that Nociscan statistically dominates Provocative Discography (PD) because PD is more costly and less effective.
“An evidence-based process for accurately identifying a source for low back pain is valuable to improve the cost-effectiveness of operative and non-operative management strategies,” said Leslie Wilson, PhD, Professor in the Department of Medicine and the Department of Clinical Pharmacy at the University of California San Francisco. “The economic model includes a decision tree comparing Nociscan with PD based on peer-reviewed data. The incremental cost-effectiveness ratio (ICER) confirms that Nociscan statistically dominates PD, with a Monte Carlo sensitivity analysis illustrating Nociscan dominates over a wide willingness-to-pay range. In total, Nociscan can save the US healthcare system from $283M to $441M annually.”
Chronic low back pain (cLBP) is a global healthcare problem, with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Conventional imaging and diagnostics provide valuable structural information but struggle to identify the source of the pathogenic pain. Low surgical success rates (41-57%)1,2 are expected, especially for patients suffering from Discogenic Chronic Low Back Pain (DCLP).
$ACON booooooom $1.77. No papertrading and dumping on followers or team members. LEARN TO TRADE SO THAT YOU DONT HAVE TO PUMP 🙂 https://t.co/xkyE2jpxyx
“We are pleased with the cost-effectiveness abstract results,” said Ryan Bond, Chief Strategy Officer at Aclarion. “We believe the results illustrating Nociscan’s outperformance over provocative discography will be important to our physician customers and their patients, but will also speak clearly to the payer community, who are constantly challenged to reconcile the health outcomes achieved for the dollars they spend; the value in healthcare.”
It’s worth noting that Provocative Discography and MR Spectroscopy are commonly used as standard procedures for diagnosing chronic low back pain (cLBP). However, let’s take a closer look at both methods to understand why Nociscan could significantly improve the standard of care.
To Discover the Inside Scoop on ACON, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
About Provocative Discography (PD)
Provocative discography, or disc stimulation or discography, is a diagnostic procedure used to evaluate and identify the source of chronic low back pain. It is primarily performed when other diagnostic tests, such as imaging studies like MRI or CT scans, have failed to explain the pain clearly.
During provocative discography, a contrast dye is injected into one or more intervertebral discs in the spine. The procedure is usually performed under local anesthesia and fluoroscopic guidance, allowing the physician to visualize the needle placement and the dye.
The procedure aims to reproduce the patient’s pain symptoms and determine whether the injected disc(s) is the source of the pain. The dye increases the pressure inside the disc, which may provoke pain in individuals with disc-related issues, such as disc degeneration, herniation, or tears.
After injecting the dye, the patient is asked to provide feedback on their pain experience. They may be asked to rate the intensity and location of any pain or discomfort during the procedure. This feedback helps the physician determine if the injected disc is causing the pain.
Provocative discography is considered controversial and somewhat invasive. It carries certain risks, including disc infection, nerve damage, or worsening pain. Therefore, it is typically reserved for cases where the cause of the back pain is uncertain, and the procedure’s potential benefits outweigh the risks.
MR Spectroscopy
Magnetic resonance spectroscopy (MRS) is a medical imaging technique that provides information about the chemical composition and metabolism of tissues in the body. It uses the same technology as magnetic resonance imaging (MRI) but focuses on analyzing specific substances or metabolites within the tissues. By measuring the levels of these metabolites, MRS can help diagnose and monitor various diseases and conditions, such as tumors, brain disorders, and metabolic disorders. It provides insights into the biochemical processes inside the body, complementing traditional imaging methods and aiding in a more comprehensive understanding of health and disease.
Weaker Signals: MRS detects weaker signals than regular MRI scans, making separating the desired information from background noise harder. This can result in less clear and accurate data.
Less Detailed Images: MRS provides less detailed pictures than regular MRI scans. It’s like zooming out to see a larger area rather than focusing on a specific spot. This can make it challenging to pinpoint specific problem areas.
Overlapping Signals: Sometimes, the signals from different bodily substances overlap, making it challenging to accurately identify and measure individual substances. It’s like trying to hear one person speaking in a crowded room—it can get confusing.
Inconsistent Results: MRS relies on precise measurements of the chemical properties of tissues, but variations in the magnetic field can cause inconsistencies in the data. It’s like trying to measure something accurately, but the measuring tools aren’t perfectly reliable.
Limited Information: While MRS can detect various substances in the body, it can only measure a limited number of them accurately. So, there might be essential substances it can’t identify or measure correctly.
Expertise Required: Interpreting MRS data and getting accurate results requires specialized knowledge and skills. It’s like needing an expert who understands all the technical details to make sense of the information.
Despite these challenges, MRS is still valuable in certain areas of medicine and research. Scientists and engineers continuously improve technology to overcome these limitations and make it more helpful in diagnosing and studying various health conditions.
If You’d like to dive deeper into the technology and what Aclarion Inc. ($ACON) is doing – here are a couple in-depth videos from experts:
The Nociscan cost-effectiveness abstract showcases the superiority of Nociscan over provocative discography regarding both effectiveness and cost savings. The technology also seems to have substantial improvements in patient outcomes over MR spectroscopy as well. This abstract provides evidence that implementing Nociscan as a diagnostic tool for chronic low back pain (cLBP) can result in substantial financial benefits for the US healthcare system – saving them anywhere from $283M to $441M annually.
We will update you on ACON when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
On October 2nd, 2023, IceCure Medical (NASDAQ: ICCM) shares surged by over 50% following exciting news presented at a major medical event, the European Society of Breast Imaging. Their cutting-edge ProSense® System, designed for minimally invasive cryoablation, is marketed and sold worldwide for its cleared indications in the U.S., Europe, and China. More recently they gained approvals in India, and Brazil and have additional distribution through MC Medical to continue expanding in Europe. More importantly, the latest independent study confirms that the technology is a safe & effective outpatient procedure for breast cancer, with 96.8% success rate.
More Background:
Their system has the potential to revolutionize cancer treatment not only for breast cancer, but also for kidney, bone, and lung cancers. To date, the system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.
During the event, Dr. Lucía Graña-López, a radiologist specializing in breast and women’s imaging, led an independent study. The study explored cryoablation as a viable alternative to surgery for early-stage breast cancer in patients who preferred a non-surgical route. The results were promising, suggesting that cryoablation could be a successful treatment option, particularly for patients hesitant about traditional surgery.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Clinical Study:
The study involved 31 patients with early-stage breast cancer who opted out of surgery, and the outcomes showed that cryoablation was well-tolerated with no major complications. This alternative approach could potentially be a game-changer, especially for breast cancer, which is one of the most prevalent cancers globally. Many patients, particularly older individuals, are seeking less invasive alternatives to surgery, making cryoablation an appealing option.
Dr. Graña-López envisions cryoablation becoming a significant alternative to surgery, particularly for early-stage breast cancer in post-menopausal women. Moreover she believes this technology could reshape how we approach treatment in other indications, particularly for kidney, lung, and thyroid gland cancers.
These results from this independent study are are in line with the ongoing ICE3 study, the largest of its kind in the U.S., set to conclude in early 2024.
We will update you on ICCM when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This unique test directly detects six biothreat pathogens from a blood sample.
Spotting Biothreats Faster:
T2Biothreat Panel is a game-changer, being the first and only FDA-approved product that can spot these critical biothreat pathogens simultaneously. T2 Biosystems proudly stands as the first U.S. company to achieve this milestone, reshaping the field of biothreat detection.
Big Investor Sells:
Interestingly while celebrating this achievement, a significant investor, CR Group (CRG), decided to sell off a substantial chunk of shares. This sell-off, totaling 24.81 million shares, took place between Sept. 20 and Sept. 26. The timing of this sell-off alongside the FDA clearance raises some eyebrows.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
New CDC Guidelines:
Regardless of CR Group selling, there still appears to be a massive opportunity according to many retail investors. Following new CDC guidelines, the U.S. government now mandates that all hospitals in the country must adopt rapid testing protocols to combat the sepsis pandemic by 2026, or risk losing Medicare funding.
T2 Biosystems stands as the exclusive FDA-cleared product capable of achieving 100% accurate sepsis detection within 3 to 5 hours. Anticipating widespread adoption of T2 instruments in hospitals, the CEO foresees significant revenue generation, potentially reaching $1.3 billion annually, given the mandate.
This development drastically alters the landscape, potentially influencing the stock’s trajectory positively. With the ongoing surge in manufacturing hires and likely acceleration in orders, coupled with potential government contracts or international sales, many beleive T2 Biosystems presents an undervalued opportunity for investors.
What Borrowing Costs Tell Us:
Another interesting indicator to look at is the cost to borrow (CTB) fee. In terms of TTOO’s case, the stock has seen a massive surge in CTB fees, indicating a high demand from short sellers. When compared to the average CTB fee for other stocks, it’s pretty drastic. While this is typically not a very positive sign, retail investors seem to be buzzing with interest, given there also could be a potential short squeeze if enough buying comes in to trap the shorts.
Better News for Patients:
But let’s not forget the real impact and that’s what TTOO can do for patients. @ChengKeki a user from Twitter also shared an article about Butler Memorial Hospital and their approach to Sepsis. The hospital came up with a 2 step approach to expedite patient care. They’re utilizing the Beckman Coulter automation line to identify changes in a person’s blood cells that might indicate the development of sepsis. Which apparently has only been used in Europe and they’re the first in the US with the technology. Then shortly after, they use T2 Biosystems panels that as you know, quicken the process from 36 hours, to just 3-5 hours.
Catching sepsis quickly is crucial because it’s a life-threatening condition that rapidly progresses throughout your body and can lead to death if not promptly diagnosed and treated. Sepsis occurs when the body responds improperly to an infection, causing widespread inflammation and potentially damages multiple organ systems. Early detection allows for immediate medical intervention.
Conclusion:
T2 Biosystems is hitting major milestones, not only in the market but in improving critical healthcare processes. The company is also a major hit with retail investors and continues to trade an astronomical amount of shares daily, the current average is ~115M shares. The FDA approval and its implications, along with the positive shift in sepsis diagnosis, showcase T2 Biosystems’ growing role in healthcare. Keep an eye on how this progresses—it’s exciting for both investors and patients alike.
We will update you on TTOO when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).
More Background:
Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.
Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.
He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.
We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.